Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > 57,000 views, THTX YouTube video link below
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by stephanedodieron Sep 27, 2022 2:19pm
133 Views
Post# 34990040

RE:RE:RE:RE:RE:RE:57,000 views, THTX YouTube video link below

RE:RE:RE:RE:RE:RE:57,000 views, THTX YouTube video link belowCan we agree on the fact that ....

1 - THTX is currently undervalued
2 - THTX is not very visible on many message board
3 - ME (and maybe a lot of us) would like to see THTX SP going up

So, what ca WE do ...

1 - Wait and pray (or the reverse)
2 - Speculate, and discuss (on the MB or at the Peel Pub) and wait
3 - OR, create a communication strategy and target the 1000 StockTwits follower with a mission to educate them with the objective to increase THTX visibility ?

How to execute

Let's just stat posting the good stuff on that boad too, if we can post 25 to 50 message a day on ST then we might get retail investor attention.

GLTA ! in the meanwhile, I will wait for Cantor tomorrow, a nice possible PR on 1b, the business update  mid-october etc etc etc....
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities